NOEMA PHARMA
Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema’s research and development is focused on understanding and meeting patient needs using their novel therapies. Noema Pharma was founded in 2019 and is based in Basel-Stadt, Switzerland.
NOEMA PHARMA
Social Links:
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2019-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.noemapharma.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
54 M CHF
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Font Awesome Global Site Tag
Current Advisors List
Current Employees Featured
Founder
Investors List
Polaris Partners
Polaris Partners investment in Series A - Noema Pharma
BioMedPartners
BioMedPartners investment in Series A - Noema Pharma
Gilde Healthcare
Gilde Healthcare investment in Series A - Noema Pharma
Invus
Invus investment in Series A - Noema Pharma
Sofinnova Partners
Sofinnova Partners investment in Series A - Noema Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-28 | Noema Pharma Appoints Michael Gutch as Chief Financial Officer |
Official Site Inspections
http://www.noemapharma.com Semrush global rank: 5.08 M Semrush visits lastest month: 1.62 K
- Host name: noemapharma.wpmudev.host
- IP address: 45.76.83.58
- Location: Frankfurt am Main Germany
- Latitude: 50.1103
- Longitude: 8.7147
- Timezone: Europe/Berlin
- Postal: 60314
More informations about "Noema Pharma"
Noema Pharma - BEYOND SYMPTOM CONTROL
Developing therapies to help both orphan and larger patient populations with conditions of the brain and nervous system live their lives to the fullest. Noema Pharma is a clinical-stage …See details»
Who We Are | Noema Pharma
Our leadership team has extensive experience with global biotech and pharmaceutical companies and a proven track record of developing and commercializing treatments for central nervous system (CNS) disorders.See details»
Noema Pharma - Crunchbase Company Profile
Noema Pharma is a biotech company that develops therapies to address disabling symptoms in conditions of the brain and nervous system. View contacts for Noema Pharma to access new leads and connect with decision-makers.See details»
Noema Pharma - LinkedIn
Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema’s research and development...See details»
Noema Pharma AG – Swiss Biotech
Noema Pharma is a clinical-stage biotech company targeting debilitating central nervous systems indications. Our pipeline contains novel therapies designed to address CNS disorders in order …See details»
Noema Pharma raises CHF 103 million (USD 112 …
BASEL, Switzerland, March 7, 2023 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced that it has successfully closed an oversubscribed Series B …See details»
Noema Pharma, founded by Sofinnova Partners, raises CHF 103 …
Mar 7, 2023 · Noema is a clinical-stage biopharmaceutical company focused on central nervous system disorders. Existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare …See details»
Noema Pharma — Sofinnova Partners
Noema is a Swiss-based company targeting orphan neurological disorders characterized by imbalanced neuronal networks. The company is developing four mid-clinical-stage therapeutic …See details»
Noema Pharma at the Swiss Biotech Day
Noema Pharma is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks.See details»
Noema Pharma - Craft
Noema Pharma is a biotech company developing therapies to address disabling symptoms in orphan conditions of the brain and nervous system. It aims to develop drugs to treat rare …See details»
Noema Pharma raises CHF54 million in Series A financing
Dec 1, 2020 · Noema Pharma (www.noemapharma.com) is a Swiss-based company targeting orphan neurological disorders characterized by imbalanced neuronal networks. The company …See details»
Noema Pharma AG - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Noema Pharma AG of Basel, BASEL-STADT. Get the latest business insights from Dun & Bradstreet.See details»
NEWS & EVENTS - Noema Pharma
Jun 21, 2021 · BASEL, Switzerland, January 3, 2024 — Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that …See details»
Noema Pharma Company Profile 2024: Valuation, Funding
Operator of a biotechnology company intended to address the disabling symptoms in orphan conditions of the central nervous system.See details»
Noema Pharma - Overview, News & Similar companies - ZoomInfo
Dec 7, 2023 · Noema Pharma (www.noemapharma.com) is a Swiss-based company targeting neurological disorders characterized by imbalanced neuronal networks. The company is …See details»
Noema Pharma Announces FDA Investigational New Drug (IND) …
Jun 27, 2022 · BASEL, Switzerland and BOSTON, June 27, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system …See details»
Noema Pharma Announces First Patients Dosed in Phase 2b Study …
BASEL, Switzerland, Oct. 30, 2024 – Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global Phase 2b study …See details»
Noema Pharma Announces First Patient Dosed in Phase 2a
May 22, 2024 · Noema Pharma is a clinical-stage biotech company advancing a differentiated portfolio of transformative therapeutics utilizing first-in-disease approaches targeting orphan …See details»
Noema Pharma | EU-Startups
Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system.See details»
Noema Pharma initiates Phase 2a Allevia study of PDE10A …
Basel, August 5, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the initiation of its first clinical trial, …See details»